Cargando…

Significance Analysis of Prognostic Signatures

A major goal in translational cancer research is to identify biological signatures driving cancer progression and metastasis. A common technique applied in genomics research is to cluster patients using gene expression data from a candidate prognostic gene set, and if the resulting clusters show sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Andrew H., Knoblauch, Nicholas W., Hefti, Marco M., Kaplan, Jennifer, Schnitt, Stuart J., Culhane, Aedin C., Schroeder, Markus S., Risch, Thomas, Quackenbush, John, Haibe-Kains, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554539/
https://www.ncbi.nlm.nih.gov/pubmed/23365551
http://dx.doi.org/10.1371/journal.pcbi.1002875
_version_ 1782256914450612224
author Beck, Andrew H.
Knoblauch, Nicholas W.
Hefti, Marco M.
Kaplan, Jennifer
Schnitt, Stuart J.
Culhane, Aedin C.
Schroeder, Markus S.
Risch, Thomas
Quackenbush, John
Haibe-Kains, Benjamin
author_facet Beck, Andrew H.
Knoblauch, Nicholas W.
Hefti, Marco M.
Kaplan, Jennifer
Schnitt, Stuart J.
Culhane, Aedin C.
Schroeder, Markus S.
Risch, Thomas
Quackenbush, John
Haibe-Kains, Benjamin
author_sort Beck, Andrew H.
collection PubMed
description A major goal in translational cancer research is to identify biological signatures driving cancer progression and metastasis. A common technique applied in genomics research is to cluster patients using gene expression data from a candidate prognostic gene set, and if the resulting clusters show statistically significant outcome stratification, to associate the gene set with prognosis, suggesting its biological and clinical importance. Recent work has questioned the validity of this approach by showing in several breast cancer data sets that “random” gene sets tend to cluster patients into prognostically variable subgroups. This work suggests that new rigorous statistical methods are needed to identify biologically informative prognostic gene sets. To address this problem, we developed Significance Analysis of Prognostic Signatures (SAPS) which integrates standard prognostic tests with a new prognostic significance test based on stratifying patients into prognostic subtypes with random gene sets. SAPS ensures that a significant gene set is not only able to stratify patients into prognostically variable groups, but is also enriched for genes showing strong univariate associations with patient prognosis, and performs significantly better than random gene sets. We use SAPS to perform a large meta-analysis (the largest completed to date) of prognostic pathways in breast and ovarian cancer and their molecular subtypes. Our analyses show that only a small subset of the gene sets found statistically significant using standard measures achieve significance by SAPS. We identify new prognostic signatures in breast and ovarian cancer and their corresponding molecular subtypes, and we show that prognostic signatures in ER negative breast cancer are more similar to prognostic signatures in ovarian cancer than to prognostic signatures in ER positive breast cancer. SAPS is a powerful new method for deriving robust prognostic biological signatures from clinically annotated genomic datasets.
format Online
Article
Text
id pubmed-3554539
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35545392013-01-30 Significance Analysis of Prognostic Signatures Beck, Andrew H. Knoblauch, Nicholas W. Hefti, Marco M. Kaplan, Jennifer Schnitt, Stuart J. Culhane, Aedin C. Schroeder, Markus S. Risch, Thomas Quackenbush, John Haibe-Kains, Benjamin PLoS Comput Biol Research Article A major goal in translational cancer research is to identify biological signatures driving cancer progression and metastasis. A common technique applied in genomics research is to cluster patients using gene expression data from a candidate prognostic gene set, and if the resulting clusters show statistically significant outcome stratification, to associate the gene set with prognosis, suggesting its biological and clinical importance. Recent work has questioned the validity of this approach by showing in several breast cancer data sets that “random” gene sets tend to cluster patients into prognostically variable subgroups. This work suggests that new rigorous statistical methods are needed to identify biologically informative prognostic gene sets. To address this problem, we developed Significance Analysis of Prognostic Signatures (SAPS) which integrates standard prognostic tests with a new prognostic significance test based on stratifying patients into prognostic subtypes with random gene sets. SAPS ensures that a significant gene set is not only able to stratify patients into prognostically variable groups, but is also enriched for genes showing strong univariate associations with patient prognosis, and performs significantly better than random gene sets. We use SAPS to perform a large meta-analysis (the largest completed to date) of prognostic pathways in breast and ovarian cancer and their molecular subtypes. Our analyses show that only a small subset of the gene sets found statistically significant using standard measures achieve significance by SAPS. We identify new prognostic signatures in breast and ovarian cancer and their corresponding molecular subtypes, and we show that prognostic signatures in ER negative breast cancer are more similar to prognostic signatures in ovarian cancer than to prognostic signatures in ER positive breast cancer. SAPS is a powerful new method for deriving robust prognostic biological signatures from clinically annotated genomic datasets. Public Library of Science 2013-01-24 /pmc/articles/PMC3554539/ /pubmed/23365551 http://dx.doi.org/10.1371/journal.pcbi.1002875 Text en © 2013 Beck et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Beck, Andrew H.
Knoblauch, Nicholas W.
Hefti, Marco M.
Kaplan, Jennifer
Schnitt, Stuart J.
Culhane, Aedin C.
Schroeder, Markus S.
Risch, Thomas
Quackenbush, John
Haibe-Kains, Benjamin
Significance Analysis of Prognostic Signatures
title Significance Analysis of Prognostic Signatures
title_full Significance Analysis of Prognostic Signatures
title_fullStr Significance Analysis of Prognostic Signatures
title_full_unstemmed Significance Analysis of Prognostic Signatures
title_short Significance Analysis of Prognostic Signatures
title_sort significance analysis of prognostic signatures
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554539/
https://www.ncbi.nlm.nih.gov/pubmed/23365551
http://dx.doi.org/10.1371/journal.pcbi.1002875
work_keys_str_mv AT beckandrewh significanceanalysisofprognosticsignatures
AT knoblauchnicholasw significanceanalysisofprognosticsignatures
AT heftimarcom significanceanalysisofprognosticsignatures
AT kaplanjennifer significanceanalysisofprognosticsignatures
AT schnittstuartj significanceanalysisofprognosticsignatures
AT culhaneaedinc significanceanalysisofprognosticsignatures
AT schroedermarkuss significanceanalysisofprognosticsignatures
AT rischthomas significanceanalysisofprognosticsignatures
AT quackenbushjohn significanceanalysisofprognosticsignatures
AT haibekainsbenjamin significanceanalysisofprognosticsignatures